362 related articles for article (PubMed ID: 16230675)
1. Prognostic factors in HIV-related diffuse large-cell lymphoma: before versus after highly active antiretroviral therapy.
Lim ST; Karim R; Tulpule A; Nathwani BN; Levine AM
J Clin Oncol; 2005 Nov; 23(33):8477-82. PubMed ID: 16230675
[TBL] [Abstract][Full Text] [Related]
2. AIDS-related Burkitt's lymphoma versus diffuse large-cell lymphoma in the pre-highly active antiretroviral therapy (HAART) and HAART eras: significant differences in survival with standard chemotherapy.
Lim ST; Karim R; Nathwani BN; Tulpule A; Espina B; Levine AM
J Clin Oncol; 2005 Jul; 23(19):4430-8. PubMed ID: 15883411
[TBL] [Abstract][Full Text] [Related]
3. Clinical features and predictors of survival of AIDS-related non-Hodgkin's lymphoma in a population-based case series in Sydney, Australia.
Robotin MC; Law MG; Milliken S; Goldstein D; Garsia RJ; Dolan GM; Kaldor JM; Grulich AE
HIV Med; 2004 Sep; 5(5):377-84. PubMed ID: 15369514
[TBL] [Abstract][Full Text] [Related]
4. AIDS and non-Hodgkin's lymphoma. Experience at an oncological center in Mexico.
Cornejo-Juárez P; Volkow-Fernández P; Avilés-Salas A; Calderón-Flores E
Rev Invest Clin; 2008; 60(5):375-81. PubMed ID: 19227434
[TBL] [Abstract][Full Text] [Related]
5. The International Prognostic Index can be used as a guide to treatment decisions regarding patients with human immunodeficiency virus-related systemic non-Hodgkin lymphoma.
Rossi G; Donisi A; Casari S; Re A; Cadeo G; Carosi G
Cancer; 1999 Dec; 86(11):2391-7. PubMed ID: 10590382
[TBL] [Abstract][Full Text] [Related]
6. The prognosis of HIV-infected patients with diffuse large B-cell lymphoma treated with chemotherapy and highly active antiretroviral therapy is similar to that of HIV-negative patients receiving chemotherapy.
Navarro JT; Lloveras N; Ribera JM; Oriol A; Mate JL; Feliu E
Haematologica; 2005 May; 90(5):704-6. PubMed ID: 15921395
[TBL] [Abstract][Full Text] [Related]
7. Intensive chemotherapy with cyclophosphamide, doxorubicin, high-dose methotrexate/ifosfamide, etoposide, and high-dose cytarabine (CODOX-M/IVAC) for human immunodeficiency virus-associated Burkitt lymphoma.
Wang ES; Straus DJ; Teruya-Feldstein J; Qin J; Portlock C; Moskowitz C; Goy A; Hedrick E; Zelenetz AD; Noy A
Cancer; 2003 Sep; 98(6):1196-205. PubMed ID: 12973843
[TBL] [Abstract][Full Text] [Related]
8. Treatment and prognosis of AIDS-related lymphoma in the era of highly active antiretroviral therapy: findings from the Swiss HIV Cohort Study.
Simcock M; Blasko M; Karrer U; Bertisch B; Pless M; Blumer L; Vora S; Robinson JO; Bernasconi E; Terziroli B; Moirandat-Rytz S; Furrer H; Hirschel B; Vernazza P; Sendi P; Rickenbach M; Bucher HC; Battegay M; Koller MT;
Antivir Ther; 2007; 12(6):931-9. PubMed ID: 17926647
[TBL] [Abstract][Full Text] [Related]
9. Improved survival and chemotherapy response among patients with AIDS-related non-Hodgkin's lymphoma receiving highly active antiretroviral therapy.
Diamond C; Taylor TH; Im T; Miradi M; Anton-Culver H
Hematol Oncol; 2006 Sep; 24(3):139-45. PubMed ID: 16604565
[TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of cyclophosphamide, adriamycin, vincristine, prednisone and rituximab in patients with human immunodeficiency virus-associated diffuse large B-cell lymphoma: results of a phase II trial.
Ribera JM; Oriol A; Morgades M; González-Barca E; Miralles P; López-Guillermo A; Gardella S; López A; Abella E; García M;
Br J Haematol; 2008 Feb; 140(4):411-9. PubMed ID: 18162120
[TBL] [Abstract][Full Text] [Related]
11. The changing face of HIV-associated lymphoma: what can we learn about optimal therapy inl the post highly active antiretroviral therapy era?
Clayton A; Mughal T
Hematol Oncol; 2004 Sep; 22(3):111-20. PubMed ID: 15991221
[TBL] [Abstract][Full Text] [Related]
12. Delayed progression to death and to AIDS in a Hong Kong cohort of patients with advanced HIV type 1 disease during the era of highly active antiretroviral therapy.
Wong KH; Chan KC; Lee SS
Clin Infect Dis; 2004 Sep; 39(6):853-60. PubMed ID: 15472819
[TBL] [Abstract][Full Text] [Related]
13. Prognostic factors and outcome of human herpesvirus 8-associated primary effusion lymphoma in patients with AIDS.
Boulanger E; Gérard L; Gabarre J; Molina JM; Rapp C; Abino JF; Cadranel J; Chevret S; Oksenhendler E
J Clin Oncol; 2005 Jul; 23(19):4372-80. PubMed ID: 15994147
[TBL] [Abstract][Full Text] [Related]
14. Phase II trial of infusional cyclophosphamide, doxorubicin, and etoposide in patients with HIV-associated non-Hodgkin's lymphoma: an Eastern Cooperative Oncology Group Trial (E1494).
Sparano JA; Lee S; Chen MG; Nazeer T; Einzig A; Ambinder RF; Henry DH; Manalo J; Li T; Von Roenn JH
J Clin Oncol; 2004 Apr; 22(8):1491-500. PubMed ID: 15084622
[TBL] [Abstract][Full Text] [Related]
15. Changes in acquired immunodeficiency syndrome-related non-Hodgkin lymphoma in the era of highly active antiretroviral therapy: incidence, presentation, treatment, and survival.
Diamond C; Taylor TH; Aboumrad T; Anton-Culver H
Cancer; 2006 Jan; 106(1):128-35. PubMed ID: 16329140
[TBL] [Abstract][Full Text] [Related]
16. [Successful treatment with hyper-CVAD and highly active anti-retroviral therapy (HAART) for AIDS-related Burkitt lymphoma].
Suzuki K; Nakazato T; Sanada Y; Mihara A; Tachikawa N; Kurai H; Yoshimura Y; Hayashi H; Yoshida S; Kakimoto T
Rinsho Ketsueki; 2010 Mar; 51(3):207-12. PubMed ID: 20379116
[TBL] [Abstract][Full Text] [Related]
17. High-dose therapy plus autologous hematopoietic stem cell transplantation for human immunodeficiency virus (HIV)-related lymphoma: results and impact on HIV disease.
Gabarre J; Marcelin AG; Azar N; Choquet S; Lévy V; Lévy Y; Tubiana R; Charlotte F; Norol F; Calvez V; Spina M; Vernant JP; Autran B; Leblond V
Haematologica; 2004 Sep; 89(9):1100-8. PubMed ID: 15377471
[TBL] [Abstract][Full Text] [Related]
18. Presence of a high-grade component in gastric mucosa-associated lymphoid tissue (MALT) lymphoma is not associated with an adverse prognosis.
Ang MK; Hee SW; Quek R; Yap SP; Loong S; Tan L; Tao M; Lim ST
Ann Hematol; 2009 May; 88(5):417-24. PubMed ID: 18777110
[TBL] [Abstract][Full Text] [Related]
19. AIDS-related Kaposi's Sarcoma: evaluation of potential new prognostic factors and assessment of the AIDS Clinical Trial Group Staging System in the Haart Era--the Italian Cooperative Group on AIDS and Tumors and the Italian Cohort of Patients Naive From Antiretrovirals.
Nasti G; Talamini R; Antinori A; Martellotta F; Jacchetti G; Chiodo F; Ballardini G; Stoppini L; Di Perri G; Mena M; Tavio M; Vaccher E; D'Arminio Monforte A; Tirelli U;
J Clin Oncol; 2003 Aug; 21(15):2876-82. PubMed ID: 12885804
[TBL] [Abstract][Full Text] [Related]
20. Serbian lymphoma study group (SLG): the prognosis of AIDS-related non-Hodgkin's lymphoma.
Djunic I; Jevtovic DL; Ranin J; Salemovic D; Tomin D; Mihaljevic B
Biomed Pharmacother; 2008 Jan; 62(1):12-5. PubMed ID: 17629445
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
